vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and P3 Health Partners Inc. (PIII). Click either name above to swap in a different company.
P3 Health Partners Inc. is the larger business by last-quarter revenue ($384.8M vs $359.9M, roughly 1.1× AdvanSix Inc.). AdvanSix Inc. runs the higher net margin — -0.8% vs -19.6%, a 18.8% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 3.8%). Over the past eight quarters, AdvanSix Inc.'s revenue compounded faster (3.4% CAGR vs -0.5%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
P3 Health Partners Inc. is a population health management and value-based care services firm operating primarily in the United States. It partners with primary care providers and health systems to deliver coordinated, high-quality care for patient populations, especially Medicare Advantage beneficiaries, focusing on improving health outcomes and lowering unnecessary healthcare costs.
ASIX vs PIII — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $384.8M |
| Net Profit | $-2.8M | $-75.5M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | -40.0% |
| Net Margin | -0.8% | -19.6% |
| Revenue YoY | 9.4% | 3.8% |
| Net Profit YoY | -892.9% | -28.8% |
| EPS (diluted) | $-0.11 | $-23.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $384.8M | ||
| Q3 25 | $374.5M | $345.3M | ||
| Q2 25 | $410.0M | $355.8M | ||
| Q1 25 | $377.8M | $373.2M | ||
| Q4 24 | $329.1M | $370.7M | ||
| Q3 24 | $398.2M | $362.1M | ||
| Q2 24 | $453.5M | $379.2M | ||
| Q1 24 | $336.8M | $388.5M |
| Q4 25 | $-2.8M | $-75.5M | ||
| Q3 25 | $-2.6M | $-31.6M | ||
| Q2 25 | $31.4M | $-20.4M | ||
| Q1 25 | $23.3M | $-20.5M | ||
| Q4 24 | $352.0K | $-58.6M | ||
| Q3 24 | $22.3M | $-46.5M | ||
| Q2 24 | $38.9M | $-12.0M | ||
| Q1 24 | $-17.4M | $-18.7M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | -40.0% | ||
| Q3 25 | -0.9% | -12.8% | ||
| Q2 25 | 7.7% | -9.6% | ||
| Q1 25 | 7.7% | -10.2% | ||
| Q4 24 | -3.9% | -37.4% | ||
| Q3 24 | 7.5% | -29.5% | ||
| Q2 24 | 11.5% | -8.3% | ||
| Q1 24 | -7.0% | -11.3% |
| Q4 25 | -0.8% | -19.6% | ||
| Q3 25 | -0.7% | -9.1% | ||
| Q2 25 | 7.7% | -5.7% | ||
| Q1 25 | 6.2% | -5.5% | ||
| Q4 24 | 0.1% | -15.8% | ||
| Q3 24 | 5.6% | -12.8% | ||
| Q2 24 | 8.6% | -3.2% | ||
| Q1 24 | -5.2% | -4.8% |
| Q4 25 | $-0.11 | $-23.08 | ||
| Q3 25 | $-0.10 | $-9.67 | ||
| Q2 25 | $1.15 | $-6.23 | ||
| Q1 25 | $0.86 | $-6.28 | ||
| Q4 24 | $0.02 | $-23.13 | ||
| Q3 24 | $0.82 | $-15.70 | ||
| Q2 24 | $1.43 | $-7.37 | ||
| Q1 24 | $-0.65 | $-7.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $25.0M |
| Total DebtLower is stronger | — | $228.4M |
| Stockholders' EquityBook value | $815.2M | $-155.2M |
| Total Assets | $1.7B | $656.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $25.0M | ||
| Q3 25 | $23.7M | $37.7M | ||
| Q2 25 | $18.4M | $38.6M | ||
| Q1 25 | $8.3M | $40.1M | ||
| Q4 24 | $19.6M | $38.8M | ||
| Q3 24 | $17.3M | $63.0M | ||
| Q2 24 | $12.1M | $73.1M | ||
| Q1 24 | $20.6M | $27.3M |
| Q4 25 | — | $228.4M | ||
| Q3 25 | — | $252.8M | ||
| Q2 25 | — | $182.0M | ||
| Q1 25 | — | $171.1M | ||
| Q4 24 | — | $108.9M | ||
| Q3 24 | — | $133.2M | ||
| Q2 24 | — | $133.1M | ||
| Q1 24 | — | $118.1M |
| Q4 25 | $815.2M | $-155.2M | ||
| Q3 25 | $818.2M | $-18.7M | ||
| Q2 25 | $823.7M | $44.5M | ||
| Q1 25 | $794.4M | $63.3M | ||
| Q4 24 | $774.6M | $75.9M | ||
| Q3 24 | $766.4M | $120.5M | ||
| Q2 24 | $746.6M | $166.8M | ||
| Q1 24 | $713.2M | $146.6M |
| Q4 25 | $1.7B | $656.6M | ||
| Q3 25 | $1.7B | $683.6M | ||
| Q2 25 | $1.6B | $731.6M | ||
| Q1 25 | $1.6B | $783.9M | ||
| Q4 24 | $1.6B | $783.4M | ||
| Q3 24 | $1.5B | $833.3M | ||
| Q2 24 | $1.5B | $892.8M | ||
| Q1 24 | $1.5B | $855.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.09× | ||
| Q1 25 | — | 2.71× | ||
| Q4 24 | — | 1.43× | ||
| Q3 24 | — | 1.11× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $-25.7M |
| Free Cash FlowOCF − Capex | $36.1M | — |
| FCF MarginFCF / Revenue | 10.0% | — |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $-25.7M | ||
| Q3 25 | $26.6M | $-15.4M | ||
| Q2 25 | $21.1M | $-16.6M | ||
| Q1 25 | $11.4M | $-33.5M | ||
| Q4 24 | $64.2M | $-57.2M | ||
| Q3 24 | $57.3M | $-22.6M | ||
| Q2 24 | $50.2M | $-10.2M | ||
| Q1 24 | $-36.2M | $-20.0M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $-71.6M | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | 7.7% | 0.0% | ||
| Q2 24 | 7.4% | 0.0% | ||
| Q1 24 | 10.5% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
PIII
| Capitated Revenue | $366.2M | 95% |
| Health Care Patient Service | $18.6M | 5% |
| Health Care Care Coordination Management Fees | $2.7M | 1% |
